Operating leverage, not revenue, is the real test of this earnings season
Halozyme, Moderna and Sarepta show that the strongest guidance revisions pair growth with cost discipline. Top-line momentum alone is no longer the headline.
The expense line is doing real work
Most third-quarter coverage will lead with revenue. Halozyme grew total revenue 39% to $493 million. Moderna posted 29% growth to $1.3 billion. Biogen grew 11% to $2.8 billion. Those numbers are real, but they are not the most instructive part of the season.
The more telling signal is what companies are doing with costs while revenue rises. Moderna lifted its 2026 revenue growth outlook to 15%-25%, from a previous expectation of up to 10%. In the same release it improved its GAAP operating expense outlook by about $0.2 billion and raised its expected year-end cash balance to $8.1-$8.3 billion. Sarepta raised the lower end of its net product revenue guidance by $50 million and lowered the top end of its expense guidance by $25 million. Both moves point the same way: better revenue, and a tighter cost base to go with it.
CompePharma's view is that operating leverage is now the discipline that separates this season's strongest reports from its merely good ones.
Halozyme shows what leverage looks like
Halozyme makes the case most clearly. It guides to 2026 total revenue growth of 33%-38%, but adjusted EBITDA growth of 89%-96% and non-GAAP EPS growth of 111%-118%. Profit is growing at roughly two to three times the pace of sales. A royalty-heavy model, with royalty revenue up 44% to $341 million, naturally produces that gap.
Sarepta is a smaller version of the same story. It reported $323.8 million of net product revenue, positive cash flow and non-GAAP operating income of $22.9 million. Its GAAP operating result was a loss of $9.0 million. The company is trimming expense guidance while preparing Phase 3 development in two programs, SRP-1003 in DM1 and SRP-1001 in FSHD. Whether the discipline holds through Phase 3 spending is the open question.
The strongest counter-argument
The obvious objection is that you cannot cut your way to a franchise. Halozyme's leverage is a feature of its royalty model, and few companies can copy it. A lower expense outlook can also reflect timing or a smaller base rather than durable efficiency. If discipline comes at the expense of the pipeline, today's margin becomes tomorrow's gap.
The evidence this season does not show that trade-off. Moderna secured U.S. approval of mFLUSIVA, its fifth approved product globally, and reported positive Phase 3 data for intismeran while lowering its cost outlook. Viatris credits an enterprise-wide strategic review for strengthening the company and is still advancing its Innovative Medicines strategy through the planned Pacira BioSciences acquisition, expected to close by the end of November. Discipline and investment are sitting side by side in these reports. The companies that can do both are the ones raising guidance.
The counter has force in one respect. Not every company has the revenue base to absorb a stumble. Prothena reported net cash used in operating and investing activities of $12.0 million in the quarter and ended with $272.2 million in cash and restricted cash. For a late-stage biotech that is a long runway, but it has no operating leverage to lean on. Its progress depends on partners such as Novo, which presented post hoc coramitug analyses in ATTR-CM.
What this means for the industry
Revenue growth can be bought, licensed or launched into. Operating leverage has to be managed, quarter after quarter, in the budget. Biogen shows the price of acquired growth: its Growth Portfolio revenue rose 49%, helped by the Apellis products, yet it reported a GAAP diluted EPS of $(0.14) on transaction-related charges. Its non-GAAP EPS of $2.62 reflects $284 million of acquired IPR&D, upfront and milestone expense. It still raised the lower end of its full-year non-GAAP EPS range to $12.20-$13.00. Growth that arrives with its own cost still has to prove it can fall to the bottom line.
The industry's next test is whether leverage survives the next round of launches and Phase 3 programs. Investors and partners will judge that on the expense line as much as on sales.
What leaders should do
- Report growth and cost trajectory together. Show how much of any guidance raise comes from revenue and how much from expense, so leverage is visible rather than assumed.
- Protect late-stage R&D while trimming elsewhere. Moderna and Sarepta suggest discipline is credible when pipeline milestones still advance alongside it.
- Stress-test acquired growth for margin. Before the next deal, model when integration and transaction costs fall away, so that growth bought today does not dilute the operating leverage you need.
Written by CompePharma's editorial system (AI-assisted, model claude-sonnet-5-5) strictly from the official material listed. It can contain errors; check the sources. Not investment advice.
The second act is where this quarter's money was made
The strongest results this season came from extending assets already in market, through new labels, formulations and royalties, rather than from unproven launches. That strategy has a ceiling.
A fee schedule rate is not a durable price: coverage is the real asset
Medicare's full-rate payment for EsoGuard is a milestone, but case-by-case coverage and a pending reconsideration show why payer access, not list price, decides the economics.
Plan the exit before the readout: strategic alternatives shouldn't start after a miss
Longeveron, Theriva and Silence show how much optionality depends on when boards start thinking about the endgame. The best time is before the data arrive.